PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Gadopiclenol→

Gadopiclenol PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
933983-75-6
Molecular formula
C35H54GdN7O15
Molecular weight
970.1 g/mol
Drug class
Gadolinium-based MRI contrast agentmacrocyclic non-ionic gadolinium chelate
Mechanism of action
The intact macrocyclic gadolinium chelate is paramagnetic and increases signal intensity by shortening T1 relaxation times in tissues where it distributes. It is a diagnostic contrast complex and should not be merged with other gadolinium chelates.
Indications / reported uses
  • Contrast enhancement for MRI of the central nervous system and other body regions in adults and paediatric patients aged 2 years and older with known or suspected abnormalities, under the product-specific US and EU authorisations

Sources: US DailyMed — VUEWAY (gadopiclenol) · EMA EPAR — Elucirem (gadopiclenol) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Gadopiclenol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Gadopiclenol Permitted Daily Exposure (PDE) report (the Gadopiclenol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Gadopiclenol Occupational Exposure Limit (OEL) report (the Gadopiclenol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.